ACLZ Stock | News | Quote | Stock Forum | Saturday, October 26,

New Post Public Reply Private Reply Replies (0) Message Board
Rosner
Accelerize New Media, Inc. ACLZ Company Overview 

Stock Message Board http://investorshangout.com/search?q=ACLZ&...mp;yt1=Go!

Last Updated: Saturday, October 26, 2013 02:13:29 AM

Accelerize New Media, Inc. ACLZ Current Price and Quotes
Last Price 1.49
Previous Close 1.47 Open 1.45
Daily Range 1.49 - 1.45 52wk Range 1.71 - 0.40
Volume 11,957 Dividend N/A
Average Vol (3m) 33,585 Yield N/A
Accelerize New Media, Inc. ACLZ
Company Information

2244 West Coast Highway
Suite 250
Newport Beach, CA 92663

Website: http://www.accelerizenewmedia.com
Phone: 949-515-2141

Accelerize New Media, Inc. ACLZ
Accelerize New Media, Inc. ACLZ
Financial Reportings and Disclosures

Reporting Status U.S. Reporting: SEC Filer
Audited Financials Audited
Latest Report Jun 30, 2013 10-Q
CIK 0001352952
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data

SIC - Industry Classification 7389 - Business services, misc
Incorporated In: DE, USA
Year of Inc. 2005
Employees Not Available
Company Officers/Contacts

Brian Ross President, CEO, Treasurer
Company Directors

Not Available
Service Providers

Auditor/Accountant
RBSM LLP
805 Third Avenue
Suite 902
New York, NY, 10022
United States

Legal Counsel
Not Available
Investor Relations Firm
Network 1 Financial Securities
The Galleria Building, 2 Bridge Avenue
Red Bank, NJ, 07701
United States


Accelerize New Media, Inc. ACLZ
ACLZ Security Details

Share Structure

Market Value1 $84,727,049 a/o Oct 25, 2013
Shares Outstanding 56,863,791 a/o Aug 07, 2013
Float Not Available
Authorized Shares Not Available
Par Value  0.001
Shareholders

Shareholders of Record 120 a/o Mar 07, 2013
Short Selling Data

Short Interest 0 (-100%)
Sep 13, 2013
Significant Failures to Deliver  No
Transfer Agent(s)

Pacific Stock Transfer Co.

Accelerize New Media, Inc. ACLZ Financials
Period Ending Dec 31, 2012 Dec 31, 2011 Dec 31, 2010 Dec 31, 2009
Total Revenue 5,801 2,363 1,456 3,874
Cost of Revenue 903 255 249 2,360
Gross Profit 4,898 2,108 1,207 1,513
Operating Expenses

Research and Development 933 499 419 13
Sales, General and Admin. 3,584 2,462 1,985 3,394
Non-Recurring Items - - - -
Other - - - -
Operating Income 381 (854) (1,196) (1,894)
Income From Continuing Operations

Add'l Income/Expense Items 2 - - -
Earnings Before Interest and Tax 383 (854) (1,196) (1,894)
Interest Expense 168 317 129 120
Earnings Before Tax 215 (1,171) (1,326) (2,013)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations 215 (1,171) (1,326) (2,013)
Non Recurring Events

Discontinued Operations 278 (6) 569 -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 493 (1,177) (757) (2,013)
Preferred Stock and Other Adjustments (83) (374) (407) (411)
Net Income Applicable to Common Shareholders 410 (1,551) (1,164) (2,424)

Accelerize New Media, Inc. ACLZ Recent News

Oct 15, 2013 Vista Partners Initiates Coverage on Accelerize New Media, Inc. (Ticker: ACLZ); $2.50 Target Price
Sep 17, 2013 CAKE Selected to Power Business Intelligence & Analytics for Leading Digital Media Company
Aug 13, 2013 Accelerize New Media, Inc. Reports Second Quarter 2013 Financial Results


ACLZ Accelerize New Media, Inc. Research DD Guide

Stock Message Board http://investorshangout.com/search?q=ACLZ&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/ACLZ/quote
Stock Chart http://www.otcmarkets.com/stock/ACLZ/chart
Company Info http://www.otcmarkets.com/stock/ACLZ/company-info
Recent News http://www.otcmarkets.com/stock/ACLZ/news
Financials http://www.otcmarkets.com/stock/ACLZ/financials
Filings and Disclosure http://www.otcmarkets.com/stock/ACLZ/filings
Short Sales http://www.otcmarkets.com/stock/ACLZ/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/ACLZ/insider-transactions
Research Reports http://www.otcmarkets.com/stock/ACLZ/research
Summary http://finance.yahoo.com/q?s=ACLZ
Historical Prices http://finance.yahoo.com/q/hp?s=ACLZ+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=ACLZ
Basic Chart http://finance.yahoo.com/q/bc?s=ACLZ+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=ACLZ+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=ACLZ+Headlines
Press Releases http://finance.yahoo.com/q/p?s=ACLZ+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=ACLZ+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=ACLZ+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=ACLZ+Industry
Major Holders http://finance.yahoo.com/q/mh?s=ACLZ+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=ACLZ+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=ACLZ+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=ACLZ
Balance Sheet http://finance.yahoo.com/q/bs?s=ACLZ
Cash Flow http://finance.yahoo.com/q/cf?s=ACLZ+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/ACLZ
Market Watch http://www.marketwatch.com/investing/stock/ACLZ
Bloomberg http://www.bloomberg.com/quote/ACLZ:US
Morningstar http://quotes.morningstar.com/stock/s?t=ACLZ
Bussinessweek http://investing.businessweek.com/research/st...icker=ACLZ
Barchart http://www.barchart.com/quotes/stocks/ACLZ
OTC Short Report http://otcshortreport.com/index.php?index=ACLZ
Investopedia http://www.investopedia.com/markets/stocks/ACLZ/?wa=0

List of all stock message boards and tickers for OTC BB Pinks & Penny Stocks http://investorshangout.com/board?categoryid=OTC
Scroll down for more posts ▼

Top 10 Most Recent News Articles

BASIS Bellevue Expands with New K-4 Campus

Updated Category News Views 89

A New Era for Young Learners in Bellevue When a community-driven school like BASIS Independent Bellevue makes a move to expand, it doesn't happen in a vacuum. They're not just building another campus—they're aiming to sculpt the future right here in Bellevue, and boy, do they have a plan. The new Lower School campus opening come Fall 2027 is dedicated to kiddos in...

Continue Reading
Smirnoff Launches Marvel Event with $12.99 Offer

Updated Category News Views 68

Smirnoff's Bold Move to Ride Marvel's Coattails Here we are, watching a vodka brand hitch its wagon to a Hollywood juggernaut. Smirnoff has announced a fan experience to toast Marvel Studios' "Avengers: Doomsday." Of course, this isn't just about clinking glasses; it's a marketing stunt dressed in superhero tights. The impressive part? They’re selling the razzmatazz for...

Continue Reading
Ameritas Hires Actuarial Veteran as VP in Strategic Move

Updated Category News Views 115

Shifting Gears at Ameritas: New VP Takes the Helm Well, chalk one up for Ameritas on this move. They've just brought on Ying Zhao as the new vice president of actuarial and financial strategy. It's a mouthful of a title, sure, but it's the role itself that's worth watching. Ameritas, for those not tracking, is a major player in the insurance and financial universe, doing...

Continue Reading
Amgen Q3 2026 Results: What Investors Should Know

Updated Category News Views 93

Amgen Prepares to Reveal Third Quarter 2026 Financials If there's one thing I've learned about investing, it's that the devil's in the details, and Amgen's (NASDAQ:AMGN) upcoming webcast for its third quarter 2026 financial results is exactly the kind of detail that sets market-watchers' hearts racing. Scheduled for November 3, just after the U.S. markets close, this is...

Continue Reading
Royce Global Trust: Insights on RGT's Performance

Updated Category News Views 80

Analyzing Royce Global Trust's Approach When you dig into the Royce Global Trust portfolio, what emerges is a tapestry woven through decades of grit and determination in the investing world. This closed-end fund, trading under the symbol NYSE: RGT, is no stranger to the ebbs and flows of global markets. With every tick of the clock, speculation dances around this fund's...

Continue Reading
transcosmos: Not Just Calls—Evolving Business Strategy

Updated Category News Views 110

Turning Talk into Triumphs Award chatter isn't exactly rare in this industry, but the latest accolades rolling in for transcosmos from the Best Contact Center Indonesia 2026 ain't your run-of-the-mill pat on the back. Sure, a trophy's a trophy, but when they snatch Gold in the Business Contribution category and another shiny Silver in People Development, it’s hinting at...

Continue Reading
Bloomberg Law Awards Series Celebrates Legal Excellence

Updated Category News Views 54

New Awards Shine Light on Corporate Legal Teams Here's one for the books: Bloomberg Law is rolling out a shiny new awards program called Inside In-House: Legal Departments of the Year. Now, this isn't some vanity affair because it's aimed at celebrating the folks in legal teams who make companies tick behind the scenes. Openings for nominations run through November 20,...

Continue Reading
Oracle's Bold Vision: Targeting $225B Revenue by 2030

Updated Category News Views 132

Oracle Lays Down a Bold Gauntlet Oracle Corporation (NYSE: ORCL) sure knows how to draw the spotlight. With their recent Investor Day in Vegas, they've laid out ambitions that could make even the most seasoned Wall Streeter spit out their coffee. Who would've thought they'd be betting on a whopping $225 billion in revenue by FY30? That's supposed to be a more than 35%...

Continue Reading
BD's New Liverty™ TIPS Stent: A Game Changer?

Updated Category News Views 75

Could This Be the Breakthrough for Portal Hypertension? Now, here's something that might just turn a few heads in the medical world. BD has launched their Liverty™ TIPS Stent Graft in the U.S., a move set to shake up the landscape for treating portal hypertension. This isn't just another shiny new gadget—it's a promise of more personalized patient care in a field...

Continue Reading
Ascletis' ASC30 Achieves Significant HbA1c Reductions

Updated Category News Views 73

When you dive into the world of biopharma, you never quite know what's going to grab your attention next. Today, it's Ascletis Pharma's (HKEX: 1672) GLP-1 receptor agonist, ASC30, that's piqued my interest. It just wrapped up a U.S. Phase II study with a bang, showing off with some impressive results for type 2 diabetes treatment. This ain't no half-hearted...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative AI Assistant by ClickBid Revolutionizes Fundraising

Updated Category News Views 155

ClickBid Introduces Groundbreaking AI Assistant ClickBid, recognized as a pioneer in event fundraising technology, proudly presents ClickBid Search. This is the first custom GPT-powered AI assistant tailored specifically for nonprofits, designed to offer immediate and relevant answers to help organizations optimize their event strategies. Available at no cost to all...

Continue Reading
TIER IV and TUM Drive Level 4 Autonomous Cars

Updated Category News Views 25

Autonomous Driving Gets a German Boost Well folks, looks like the autonomous vehicle scene is hitting the autobahns with more horsepower than ever before. Today’s chatter is all about how TIER IV and the Technical University of Munich (TUM) have teamed up, tapping into the grid as they ride the waves of cutting-edge NVIDIA tech. The Sparks Under the Hood: NVIDIA...

Continue Reading
Vericel Corporation's Upcoming Presentation at MedTech Conference

Updated Category News Views 147

Vericel Corporation's Engagement at the MedTech Conference CAMBRIDGE, Mass. — Vericel Corporation (NASDAQ:VCEL), a recognized leader in advanced therapies for sports medicine and severe burn care, has exciting news regarding its participation at the upcoming Truist Securities MedTech Conference. The company will be featured in a fireside chat, slated to take place at...

Continue Reading
Gildan Achieves Strong Q2 Results: Revenue and Finances Surge

Updated Category News Views 128

Gildan Reports Remarkable Growth in Second Quarter Earnings Gildan Activewear Inc. (NYSE: GIL, TSX: GIL) has achieved record net sales of $919 million during the second quarter, reflecting a strong 6.5% increase compared to the previous year. Strong Operational Performance and Profitability This quarter's operating margin stood at an impressive 21.7%, with an adjusted...

Continue Reading
MimiVax and UI Pharmaceuticals Mark Key Production Milestone

Updated Category News Views 260

MimiVax and UI Pharmaceuticals Mark Key Production Milestone MimiVax and UI Pharmaceuticals have achieved an exciting development in the field of cancer treatment with the clinical manufacture of SurVaxM, an innovative immunotherapeutic vaccine aimed at targeting glioblastoma. SurVaxM proudly stands out as the first product to be manufactured at UI Pharmaceuticals' newly...

Continue Reading